Biotech giant CSL is in talks to buy Swiss-based Vifor Pharma Group in a $10 billion-plus deal that would be its largest acquisition since it listed on the Australian Securities Exchange nearly three decades ago.
Bank of America Merrill Lynch is advising the $139 billion giant on how it can most effectively fund buying Vifor, which could include an equity raising of about $4 billion.
Loading...
Carrie LaFrenz is a senior journalist covering retail/consumer goods. She previously covered healthcare/biotech. Carrie has won multiple awards for her journalism including financial journalist of the year from The National Press Club. Connect with Carrie on Twitter. Email Carrie at carrie.lafrenz@afr.com
Jemima Whyte writes on business, specialising in companies, capital markets and innovation. Jemima has reported on business for The Australian Financial Review for more than 13 years. Email Jemima at jemima.whyte@afr.com
